Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice

Doxepin is commonly prescribed for depression and anxiety treatment. Doxepin-related disruptions to metabolism and renal/hepatic adverse effects remain unclear; thus, the underlying mechanism of action warrants further research. Here, we investigated how doxepin affects lipid change, glucose homeost...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Geng-Ruei Chang, Po-Hsun Hou, Wei-Cheng Yang, Chao-Min Wang, Pei-Shan Fan, Huei-Jyuan Liao, To-Pang Chen
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2021-03-01
Edice:	Pharmaceuticals
Témata:	doxepin obesity chromium fatty liver disease renal impairment glucose intolerance
On-line přístup:	https://www.mdpi.com/1424-8247/14/3/267
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!